ERBB2-positive breast cancer

Latest news

Tag

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial Review

This review synthesizes evidence from a phase 3 trial demonstrating improved pathological complete response rates with neoadjuvant anbenitamab and HB1801 in ERBB2-positive breast cancer, highlighting efficacy, safety, and clinical implicati

Sep 6, 2026

news

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

The DAPHNe trial demonstrates excellent 5-year outcomes for stage II–III ERBB2-positive breast cancer patients treated with an abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen, with ultrasensitive ctDNA monitoring sho

Jun 28, 2026

Oncology

Enhancing Quality of Life in ERBB2-Positive Metastatic Breast Cancer: The PRO-DUCE Trial on Electronic Symptom and Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy

The PRO-DUCE randomized trial demonstrates that electronic symptom and vital sign monitoring during trastuzumab deruxtecan therapy can preserve quality of life in ERBB2-positive metastatic breast cancer patients, with notable improvements i

Sep 11, 2025